Zulresso and the Social Determinants of Health Dynamics of America

  Zulresso (brexanolone) was recently approved as the first drug to treat post-partum depression (PPD). It is a medication, and naturally produced steroid that affects...
Funding

TriNetX Raises over $100 Million and Showing Up in More Discussions

TriNetX just recently raised another $40 million. The Cambridge, MA-based venture’s newest investors include Merck Global Health Innovation Fund, Mitsui & Co., Ltd., ITOCHU...

The ADAPTABLE Trial: RWD in Action by Using Electronic Health Records & PROs

Known as the Aspirin Study—A Patient-Centered Trial, it showcases use of Real-World Data (RWD) in clinical research.  A demonstration project of PCORnet (The National...

The Race to Commercialize a NASH Treatment Requires Money, Execution, and Results

France-based biotech venture Genfit S.A. (OTCPK: GNFTF) recently filed a preliminary prospectus for an initial public offering (IPO) of 5 million American Depository Shares...

ORIEN:  Drug Discovery and Development Collaboration

The pursuit of a cancer cure represents a truly collaborative effort requiring both altruistic cooperation and the profit motive of self-interest and entrepreneurial ingenuity. ...

UCSF Team Building Next Generation Blockchain-based Clinical Trial Management System

TrialSite News recently interviewed Daniel R. Wong of Bakar Computational Health Sciences Facility, University of California San Francisco. Mr. Wong, along with Sanchita Bhattacharya...
Roche Aquire

CHOP 20X Return in 6 years with Roche Acquisition of Spark Therapeutics

Swiss Roche Holding AG recently announced its intension to acquire U.S. biotechnology company Spark Therapeutics Inc. (Spark) as recently reported by NASDAQ. Priced at...
Patient Information

Research, Healthcare and Transparency: Is Information Valuable for the Patient?

TrialSite News recently wrote about the promise and perils of stem cell practices—with a keen eye on unethical and even unlawful medical practices called...

Hidradenitis Suppurativa Patient Website: Does It Live Up to Its Name?

Recently, a TrialSite News reader—a Hidradenitis Suppurativa (HS) patient—brought a website to our attention. Apparently, this individual, who has been struggling with HS, was...
Pharma Price

Price Watch: Does Sanofi & Regeneron Praluent Price Cut a Harbinger of Things to...

Heart disease is the number one killer in America.  A few factors contribute to this killer and high cholesterol is a major...